AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 MAY 1 - (NewsRx.com & NewsRx.net) -- Rosa Ortiz of Merchantville, New Jersey, has been named community outreach coordinator for Fox Chase Cancer Center. In this position, Ortiz will work with primarily Latina and African American women to inform them about the STAR (Study of Tamoxifen and Raloxifene) trial and encourage eligible women to participate.
A national breast cancer prevention study, STAR focuses on tamoxifen and raloxifene. Tamoxifen is approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of breast cancer in women at an increased risk of developing the disease. Raloxifene is FDA-approved for the prevention of osteoporosis but is believed to have a similar preventive value as tamoxifen and may have fewer side effects. The purpose of the study is to determine if one drug is better at preventing breast cancer than the other drug. The study also will determine which drug has fewer side effects.
To achieve this, Ortiz will work primarily from the Fox Chase-Temple Cancer Center, which ...
Source: HighBeam Research, Trial to focus on recruiting Latina and African American women.(Study...